oncogenes

Summary

Summary: Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.

Top Publications

  1. ncbi Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy
    I Bernard Weinstein
    College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Nat Clin Pract Oncol 3:448-57. 2006
  2. ncbi The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes
    Arnold J Levine
    Institute for Advanced Study, Princeton, NJ 08540, USA
    Science 330:1340-4. 2010
  3. ncbi Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells
    Christine Mayr
    Howard Hughes Medical Institute, USA
    Cell 138:673-84. 2009
  4. ncbi MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
    Yunqing Li
    Departments of Microbiology, Neurology and Pathology, University of Virginia, Charlottesville, VA 22908, USA
    Cancer Res 69:7569-76. 2009
  5. ncbi Oncogenes and cancer
    Carlo M Croce
    Department of Molecular Virology, Immunology, and Medical Genetics and the Human Cancer Genetics Program, Ohio State University Medical Center, Columbus, OH 43210, USA
    N Engl J Med 358:502-11. 2008
  6. ncbi microRNAs as oncogenes and tumor suppressors
    Baohong Zhang
    Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, TX 79409 1163, USA
    Dev Biol 302:1-12. 2007
  7. ncbi Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Andrea H Bild
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Nature 439:353-7. 2006
  8. ncbi A microRNA polycistron as a potential human oncogene
    Lin He
    Cold Spring Harbor Laboratory, Watson School of Biological Sciences, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
    Nature 435:828-33. 2005
  9. ncbi Oncogene addiction
    I Bernard Weinstein
    Herbert Irving Comprehensive Cancer Center, Department of Medicine, Columbia University Medical Center, New York, New York 10032 2704, USA
    Cancer Res 68:3077-80; discussion 3080. 2008
  10. ncbi DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    Jirina Bartkova
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Nature 434:864-70. 2005

Detail Information

Publications282 found, 100 shown here

  1. ncbi Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy
    I Bernard Weinstein
    College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Nat Clin Pract Oncol 3:448-57. 2006
    ..e. the 'Achilles' heel,' in specific cancers. Finally, we discuss the use of molecular targeted agents in combination with other anticancer agents as a strategy to optimize therapy and prevent disease recurrence...
  2. ncbi The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes
    Arnold J Levine
    Institute for Advanced Study, Princeton, NJ 08540, USA
    Science 330:1340-4. 2010
    ..switch places the emphasis on producing intermediates for cell growth and division, and it is regulated by both oncogenes and tumor suppressor genes in a number of key cancer-producing pathways...
  3. ncbi Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells
    Christine Mayr
    Howard Hughes Medical Institute, USA
    Cell 138:673-84. 2009
    In cancer cells, genetic alterations can activate proto-oncogenes, thereby contributing to tumorigenesis. However, the protein products of oncogenes are sometimes overexpressed without alteration of the proto-oncogene...
  4. ncbi MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
    Yunqing Li
    Departments of Microbiology, Neurology and Pathology, University of Virginia, Charlottesville, VA 22908, USA
    Cancer Res 69:7569-76. 2009
    ..They show that miR-34a suppresses brain tumor growth by targeting c-Met and Notch. The results also suggest that miR-34a could serve as a potential therapeutic agent for brain tumors...
  5. ncbi Oncogenes and cancer
    Carlo M Croce
    Department of Molecular Virology, Immunology, and Medical Genetics and the Human Cancer Genetics Program, Ohio State University Medical Center, Columbus, OH 43210, USA
    N Engl J Med 358:502-11. 2008
  6. ncbi microRNAs as oncogenes and tumor suppressors
    Baohong Zhang
    Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, TX 79409 1163, USA
    Dev Biol 302:1-12. 2007
    ..In addition, some miRNAs may function as oncogenes or tumor suppressors...
  7. ncbi Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Andrea H Bild
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Nature 439:353-7. 2006
    ..Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics...
  8. ncbi A microRNA polycistron as a potential human oncogene
    Lin He
    Cold Spring Harbor Laboratory, Watson School of Biological Sciences, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
    Nature 435:828-33. 2005
    ..Together, these studies indicate that non-coding RNAs, specifically microRNAs, can modulate tumour formation, and implicate the mir-17-92 cluster as a potential human oncogene...
  9. ncbi Oncogene addiction
    I Bernard Weinstein
    Herbert Irving Comprehensive Cancer Center, Department of Medicine, Columbia University Medical Center, New York, New York 10032 2704, USA
    Cancer Res 68:3077-80; discussion 3080. 2008
    ..e., the "Achilles heel") in specific cancers. Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction...
  10. ncbi DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    Jirina Bartkova
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Nature 434:864-70. 2005
    ..Similar checkpoint responses were induced in cultured cells upon expression of different oncogenes that deregulate DNA replication...
  11. ncbi An oncogene-induced DNA damage model for cancer development
    Thanos D Halazonetis
    Department of Molecular Biology and Department of Biochemistry, University of Geneva, CH 1205 Geneva, Switzerland
    Science 319:1352-5. 2008
    ..Yet recent experimental findings suggest that, in both precancerous lesions and cancers, activated oncogenes induce stalling and collapse of DNA replication forks, which in turn leads to formation of DNA DSBs...
  12. ncbi Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes
    A Ullrich
    Nature 313:756-61. 1985
    ..There are sequence homologies to human epidermal growth factor receptor and the members of the src family of oncogene products...
  13. ncbi Cancer genes and the pathways they control
    Bert Vogelstein
    Howard Hughes Medical Institute and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University Medical Institutions, Baltimore, Maryland 21231, USA
    Nat Med 10:789-99. 2004
    ..The purposes of this review are to highlight examples of progress in these areas, indicate where knowledge is scarce and point out fertile grounds for future investigation...
  14. ncbi Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    Paul T C Wan
    Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK
    Cell 116:855-67. 2004
    ..The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism...
  15. ncbi Oncogenes in melanoma
    David Polsky
    Department of Dermatology, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA
    Oncogene 22:3087-91. 2003
    ..We provide a general overview of the mechanisms of oncogene activation and the functions of oncogenes. Lastly, we review oncogenic events in melanoma.
  16. ncbi Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer
    Raffaella Di Micco
    IFOM Foundation FIRC Institute of Molecular Oncology Foundation, Milan, Italy
    Nat Cell Biol 13:292-302. 2011
    ..These results indicate that heterochromatin induced by oncogenic stress restrains DDR and suggest that the use of chromatin-modifying drugs in cancer therapies may benefit from the study of chromatin and DDR status of tumours...
  17. ncbi Oncogenes and tumor suppressor genes
    Eva Y H P Lee
    Department of Biological Chemistry and Department of Developmental and Cell Biology, University of California, Irvine, California 92697 4037, USA
    Cold Spring Harb Perspect Biol 2:a003236. 2010
    Breast cancer progression involves multiple genetic events, which can activate dominant-acting oncogenes and disrupt the function of specific tumor suppressor genes...
  18. ncbi Cancer. Addiction to oncogenes--the Achilles heal of cancer
    I Bernard Weinstein
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Science 297:63-4. 2002
  19. ncbi High-throughput oncogene mutation profiling in human cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 39:347-51. 2007
    ..This approach established robust mutation distributions spanning 17 cancer types. Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation...
  20. ncbi A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors
    P Mathijs Voorhoeve
    Division of Tumour Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cell 124:1169-81. 2006
    ..In a screen for miRNAs that cooperate with oncogenes in cellular transformation, we identified miR-372 and miR-373, each permitting proliferation and tumorigenesis ..
  21. ncbi Polarity proteins in migration and invasion
    S Etienne-Manneville
    Cell Polarity and Migration Group, Institut Pasteur and CNRS URA 2582, Paris Cedex 15, France
    Oncogene 27:6970-80. 2008
    ..The aim of this review is to highlight the molecular relationship between the control of cell polarity and the regulation of cell motility during oncogenesis...
  22. ncbi Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways
    S Song
    McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, 1400 University Avenue, Madison, WI 53706, USA
    Proc Natl Acad Sci U S A 95:2290-5. 1998
    ..Thus pRb and/or pRb-like proteins likely mediate both p53-dependent and p53-independent responses to radiation...
  23. ncbi Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus
    M D Waterfield
    Nature 304:35-9. 1983
    ..This similarity suggests a mechanism for transformation by SSV and other agents, involving expression of growth factors...
  24. ncbi Traps to catch unwary oncogenes
    A O Hueber
    Biochemistry of the Cell Nucleus Laboratory, Imperial Cancer Research Fund, London, UK
    Trends Genet 14:364-7. 1998
    ..We discuss such synergy with respect to the cooperating oncogenes MYC, RAS and BCL2.
  25. ncbi Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes
    Cathy B Moelans
    Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Mod Pathol 23:1029-39. 2010
    Several oncogenes and tumor-suppressor genes have been shown to be implicated in the development, progression and response to therapy of invasive breast cancer...
  26. ncbi In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML
    Anmaar M Abdul-Nabi
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS ONE 5:e12464. 2010
    Different fusion oncogenes in acute myeloid leukemia (AML) have distinct clinical and laboratory features suggesting different modes of malignant transformation...
  27. ncbi MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity?
    P Mathijs Voorhoeve
    Cancer and Stem Cell Biology Program, Duke NUS Graduate Medical School, 8 College Road, Singapore
    Biochim Biophys Acta 1805:72-86. 2010
    ..of tumor origin and behavior, they are causally linked to the emergence and development of cancer by acting as oncogenes or tumor suppressors...
  28. ncbi Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines
    Z Q Yang
    Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, Japan
    Cancer Res 60:4735-9. 2000
    ..Because amplified regions often harbor oncogenes and/or other tumor-associated genes, and because 9p23-24 amplification had been reported in various other types ..
  29. ncbi Many roads lead to oncogene-induced senescence
    S Courtois-Cox
    Genetics Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 2115, USA
    Oncogene 27:2801-9. 2008
    ..This review will focus on integrating current models and will highlight data that provide new insight into the signals that function to suppress human tumor development...
  30. ncbi Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer
    K A Kwei
    Department of Pathology, Stanford University, Stanford, CA 94305 5176, USA
    Oncogene 27:3635-40. 2008
    Lung cancer is a leading cause of cancer death, where the amplification of oncogenes contributes to tumorigenesis. Genomic profiling of 128 lung cancer cell lines and tumors revealed frequent focal DNA amplification at cytoband 14q13...
  31. ncbi DAPk protein family and cancer
    Devrim Gozuacik
    Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
    Autophagy 2:74-9. 2006
    ..autophagic cell death signals in response to various cellular stresses including the misregulated expression of oncogenes in pre-malignant cells...
  32. ncbi Molecular cytogenetic analysis of 11 new breast cancer cell lines
    F Forozan
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892 4470, USA
    Br J Cancer 81:1328-34. 1999
    ..One-third of these loci affected breast cancer oncogenes, whose amplifications were validated with specific probes: 17q12 (two cell lines with ERBB2 amplifications), ..
  33. ncbi p53: guardian of the genome and policeman of the oncogenes
    Alejo Efeyan
    Tumor Suppression Group, Spanish National Cancer Research Center CNIO, Madrid, Spain
    Cell Cycle 6:1006-10. 2007
    ..consists in sensing and reacting to DNA damage through the ATM/ATR and Chk1/Chk2 kinases, and "policeman of the oncogenes" that, correspondingly, consists in responding to oncogenic signaling through the p53-stabilizing protein ARF...
  34. ncbi Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor
    R F Doolittle
    Science 221:275-7. 1983
    ..The mechanism by which v-sis transforms cells could involve the constitutive expression of a protein with functions similar or identical to those of a factor active transiently during normal cell growth...
  35. ncbi Control of autophagy by oncogenes and tumor suppressor genes
    M C Maiuri
    INSERM, U848, Apoptosis Cancer and Immunity, F 94805 Villejuif, France
    Cell Death Differ 16:87-93. 2009
    Multiple oncogenes (in particular phosphatidylinositol 3-kinase, PI3K; activated Akt1; antiapoptotic proteins from the Bcl-2 family) inhibit autophagy...
  36. ncbi Chromosome aberrations in solid tumors
    Donna G Albertson
    Cancer Research Institute, University of California San Francisco, San Francisco, California 94143 0808, USA
    Nat Genet 34:369-76. 2003
    ....
  37. ncbi Spi-1 is a putative oncogene in virally induced murine erythroleukaemias
    F Moreau-Gachelin
    INSERM U 248, Faculte de Medecine Lariboisiere Saint Louis, Paris, France
    Nature 331:277-80. 1988
    ..insertional mutagenesis has been proposed as an efficient mechanism to turn on or to increase the expression of oncogenes in several avian or mammal models...
  38. ncbi The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence
    Frédérick A Mallette
    Departement de Biochimie, Universite de Montreal, Montreal, Quebec H3C 3J7, Canada
    Genes Dev 21:43-8. 2007
    ..Intriguingly, bypassing oncogene-induced senescence by inactivation of p53 and Rb did not eliminate the accumulation of oncogene-induced DNA damage foci (ODDI), suggesting a mechanism that may limit transformation in immortalized cells...
  39. ncbi Estrogens and human papilloma virus oncogenes regulate human ether-à-go-go-1 potassium channel expression
    Lorenza Díaz
    Departamento de Biologia de la Reproduccion, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Cancer Res 69:3300-7. 2009
    ..We studied hEag1 gene expression and its regulation by estradiol, antiestrogens, and human papillomavirus (HPV) oncogenes (E6/E7)...
  40. ncbi ASPP: a new family of oncogenes and tumour suppressor genes
    A Sullivan
    Ludwig Institute for Cancer Research, University College London, 91 Riding House Street, London W1W 7BS, UK
    Br J Cancer 96:196-200. 2007
    ..Thus, the ASPP family of proteins helps to determine how cells choose to die and may therefore be a novel target for cancer therapy...
  41. ncbi Oncogenic alterations of metabolism
    C V Dang
    Dept of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Trends Biochem Sci 24:68-72. 1999
    ....
  42. ncbi NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases
    M M Reddy
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Leukemia 25:281-9. 2011
    Transformation by tyrosine kinase oncogenes (TKOs) in myeloid malignancies, including BCR-ABL in chronic myeloid leukemia, FLT3ITD in acute myeloid leukemia or JAK2V617F in myeloproliferative neoplasms, is associated with increased ..
  43. ncbi Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
    M Chesi
    Genetics Department, National Cancer Institute, Bethesda, Maryland 20889 5105, USA
    Nat Genet 16:260-4. 1997
    Dysregulation of oncogenes by translocation to the IgH locus (14q32) is a seminal event in the pathogenesis of B-cell tumours. In multiple myeloma (MM), translocations to the IgH locus have been reported at an incidence of 20-60%...
  44. ncbi Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma
    Shayna E A Street
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 67:5454-60. 2007
    ..This data suggests that perforin may mediate some suppression of epithelial carcinogenesis by intervening early in the tumor development process...
  45. ncbi Mapping of the p53 and mdm-2 interaction domains
    J Chen
    Department of Molecular Biology, Princeton University, New Jersey 08544 1014
    Mol Cell Biol 13:4107-14. 1993
    ..This region contains the transactivation domain of p53, suggesting that mdm-2 may inhibit p53 function by disrupting its interaction with the general transcription machinery...
  46. ncbi Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis
    Arturo Sala
    Molecular Haematology and Cancer Biology Unit, Institute of Child Health, University College London, United Kingdom
    Adv Cancer Res 105:115-32. 2009
    ..We will discuss how and under what circumstances oncogenes and epigenetic factors modify CLU expression, with important consequences for mammalian tumorigenesis.
  47. ncbi Gammaherpesvirus 68 infection of endothelial cells requires both host autophagy genes and viral oncogenes for optimal survival and persistence
    Andrea Luísa Suárez
    Department of Microbiology, University of Colorado Denver School of Medicine, 12800 E 19th Avenue, Aurora, CO 80045, USA
    J Virol 85:6293-308. 2011
    ..Furthermore, we identified two viral oncogenes, v-cyclin and v-Bcl2, that are critical to EC survival and that modify EC proliferation and survival during ..
  48. ncbi Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma
    Xin Yan Lu
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin Street, MC 3 3320, Houston, TX 77030, USA
    Mol Cancer Res 6:937-46. 2008
    ..These results indicate that CDC5L, a cell cycle regulator important for the G2-M transition, is the most likely candidate oncogene for the 6p12-p21 amplicon found in osteosarcoma...
  49. ncbi Gene amplification in cancer
    Donna G Albertson
    Cancer Research Institute and Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Trends Genet 22:447-55. 2006
    ..Clinically, amplification has prognostic and diagnostic usefulness, and is a mechanism of acquired drug resistance...
  50. ncbi New insights into oncogene addiction found
    Ken Garber
    J Natl Cancer Inst 99:264-5, 269. 2007
  51. ncbi Oncogene-induced senescence: the bright and dark side of the response
    Vassilis G Gorgoulis
    Molecular Carcinogenesis Group, Department of Histology and Embryology, School of Medicine, University of Athens, Athens, Greece
    Curr Opin Cell Biol 22:816-27. 2010
    In late 1990s, it was shown that activated oncogenes are able to induce senescence. Since then large leaps in understanding this phenomenon have been achieved...
  52. ncbi Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts
    L M Matrisian
    EMBO J 4:1435-40. 1985
    ..is also rapidly induced by the polypeptide growth factor epidermal growth factor, providing a new link between oncogenes and growth factors...
  53. ncbi A role for HPV16 E5 in cervical carcinogenesis
    John P Maufort
    Department of Oncology and the McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, USA
    Cancer Res 70:2924-31. 2010
    ..HPV16 encodes three oncogenes: E5, E6, and E7...
  54. ncbi Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction?
    Kuan Teh Jeang
    Kuan Teh Jeang, Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, The National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncotarget 1:453-6. 2010
    ..Here we discuss the possibility that early ATL cells are Tax-oncogene-addicted while late ATL cells are oncogenic microRNA (oncomiR) - addicted. The potential utility of interrupting oncomiR addiction as a cancer treatment is broached...
  55. ncbi Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma
    Maaike van Dartel
    Department of Human Genetics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands
    Cancer Genet Cytogenet 139:91-6. 2002
    ..p12 has been found in 13%-29% of high-grade osteosarcomas, suggesting the presence of an oncogene or oncogenes that may contribute to their development...
  56. ncbi The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function
    Bodo Brueckner
    Divisions of Epigenetics and Molecular Genome Analysis, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
    Cancer Res 67:1419-23. 2007
    ..Our results thus identify let-7a-3 as an epigenetically regulated miRNA gene with oncogenic function and suggest that aberrant miRNA gene methylation might contribute to the human cancer epigenome...
  57. ncbi MicroRNAs as oncogenes and tumor suppressors
    Chang-Zheng Chen
    Department of Microbiology and Immunology, Baxter Laboratory of Genetic Pharmacology, Institute for Cancer/Stem Cell Biology and Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:1768-71. 2005
  58. ncbi PIK3CA is implicated as an oncogene in ovarian cancer
    L Shayesteh
    UCSF Cancer Center, University of California, San Francisco 941430 0808, USA
    Nat Genet 21:99-102. 1999
    ..Our observations suggest PIK3CA is an oncogene that has an important role in ovarian cancer...
  59. ncbi Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
    Jirina Bartkova
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, DK 2100 Copenhagen, Denmark
    Nature 444:633-7. 2006
    ..Thus, senescence in human preneoplastic lesions is a manifestation of oncogene-induced DNA replication stress and, together with apoptosis, provides a barrier to malignant progression...
  60. ncbi High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
    Suet F Chin
    Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R215. 2007
    ..To date, most genome-wide array comparative genomic hybridization studies have used tumor panels of relatively large tumor size and high Nottingham Prognostic Index (NPI) that are not as representative of breast cancer demographics...
  61. ncbi Seeding and propagation of untransformed mouse mammary cells in the lung
    Katrina Podsypanina
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Science 321:1841-4. 2008
    ..Mammary cells lacking oncogenic transgenes displayed a similar capacity for long-term residence in the lungs but did not form ectopic tumors...
  62. ncbi TORgeting oncogene addiction for cancer therapy
    Andrew Y Choo
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 9:77-9. 2006
    ..In the January issue of Nature Medicine, Thomas et al. identify the loss of VHL tumor suppressor gene as a potential determining factor in tumor sensitivity to rapamycin...
  63. ncbi A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas
    Kartik M Mani
    Department of Biomedical Informatics DBMI, Columbia University, New York, NY 10032, USA
    Mol Syst Biol 4:169. 2008
    ..The method consistently ranked the known gene in the top 20 (0.3%), outperforming conventional approaches in 3 of 4 cases...
  64. ncbi Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
    Lars Zender
    Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
    Cell 125:1253-67. 2006
    ..analyses delineated cIAP1, a known inhibitor of apoptosis, and Yap, a transcription factor, as candidate oncogenes in the amplicon...
  65. ncbi Oncogenes and tumour suppressors take on centrosomes
    Kenji Fukasawa
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Nat Rev Cancer 7:911-24. 2007
    ..How these proteins control centrosome duplication and function, and how their mutational activation and/or inactivation results in numeral and functional centrosome abnormalities, is discussed in this Review...
  66. ncbi Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes
    M Nees
    Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, Bethesda, Maryland, USA
    J Virol 75:4283-96. 2001
    ..Thus, high-level expression of the HPV-16 E6 protein in differentiating keratinocytes directly alters expression of genes that influence host resistance to infection and immune function...
  67. ncbi Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation
    Christine Mayr
    Howard Hughes Medical Institute and Department of Biology, Massachusetts Institute of Technology, and Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
    Science 315:1576-9. 2007
    ..Thus, losing miRNA-directed repression of an oncogene provides a mechanism for tumorigenesis, and disrupting a single miRNA-target interaction can produce an observable phenotype in mammalian cells...
  68. ncbi Targeting miR-205 in breast cancer
    Hailong Wu
    Southern Illinois University School of Medicine, Department of Medical Microbiology, Immunology and Cell Biology, 825 N Rutledge, PO Box 19626, Springfield, IL 62794, USA
    Expert Opin Ther Targets 13:1439-48. 2009
    ..malignancies and suggests a causal role of microRNAs in neoplasia, presumably because microRNAs can function as oncogenes or tumor suppressors...
  69. ncbi Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes
    Rumi Sasaki
    Virology Division, National Cancer Center Research Institute, Tokyo, Japan
    Carcinogenesis 30:423-31. 2009
    ..This first in vitro model system faithfully recapitulating the development of EOCs using normal human OSE cells should greatly facilitate further studies of EOCs...
  70. ncbi Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
    Dean W Felsher
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 68:3081-6; discussion 3086. 2008
    Cancer is a multistep process whereby genetic events that result in the activation of proto-oncogenes or the inactivation of tumor suppressor genes usurp physiologic programs mandating relentless proliferation and growth...
  71. ncbi E2F-1 functions in mice to promote apoptosis and suppress proliferation
    S J Field
    Division of Neuroscience, Children s Hospital, Boston, Massacusetts, O2115, P5USA
    Cell 85:549-61. 1996
    ..These findings suggest that while certain members of the E2F family may positively regulate cell cycle progression, E2F-1 functions to regulate apoptosis and to suppress cell proliferation...
  72. ncbi The tumor suppressor microRNA let-7 represses the HMGA2 oncogene
    Yong Sun Lee
    Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia 22908, USA
    Genes Dev 21:1025-30. 2007
    ....
  73. ncbi Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets
    Shinji Mizuarai
    Department of Cancer Research, Banyu Tsukuba Research Institute, Merck Research Laboratory, Tsukuba, Ibaraki 300 2611, Japan
    Curr Mol Med 8:774-83. 2008
    Various types of cancers are generated through mutations or dysregulations of oncogenes/tumor suppressor genes involved in cell cycles and signaling transduction pathways...
  74. ncbi Age- and sex-specific genomic profiles in non-small cell lung cancer
    William Mostertz
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    JAMA 303:535-43. 2010
    ..Gene expression profiling may be useful in examining differences underlying age- and sex-specific outcomes in non-small cell lung cancer (NSCLC)...
  75. ncbi Oncogene addiction: role of signal attenuation
    Anette Hübner
    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Dev Cell 11:752-4. 2006
    Tumors can become dependent upon signaling by oncogenes. In a recent issue of Cancer Cell, Sharma et al...
  76. ncbi Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors
    Agnieszka Piekielko-Witkowska
    Department of Biochemistry and Molecular Biology, The Medical Centre of Postgraduate Education, Warsaw, Poland
    PLoS ONE 5:e13690. 2010
    ..In this paper we hypothesized that disturbed alternative splicing in ccRCC may result from improper expression of splicing factors, mediators of splicing reactions...
  77. ncbi Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma
    Sandrine Imbeaud
    INSERM, U674, Génomique fonctionnelle des tumeurs solides, Paris, France
    Semin Liver Dis 30:75-86. 2010
    Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma (HCC) is challenging, both because of the tumor complexity and the difficulty in integrating the very large amount of data provided by different ..
  78. ncbi DSTHO: database of siRNAs targeted at human oncogenes: a statistical analysis
    Ranjit Dash
    Molecular Modeling Group, Organic Chemical Sciences, Indian Institute of Chemical Technology, Hyderabad 500007, India
    Int J Biol Macromol 38:65-9. 2006
    ..The database is designed in order to aid the synthesis of siRNAs, which target human oncogenes (OsiRNAs)...
  79. ncbi Insertional mutagenesis identifies a member of the Wnt gene family as a candidate oncogene in the mammary epithelium of int-2/Fgf-3 transgenic mice
    F S Lee
    Department of Genetics, Harvard Medical School, Boston, MA 02115
    Proc Natl Acad Sci U S A 92:2268-72. 1995
    ..This newly discovered Wnt family member was expressed in the embryo and mammary gland of virgin but not pregnant mice and represents a candidate collaborating oncogene of int-2/Fgf-3 in the mammary epithelium...
  80. ncbi From oncogene to network addiction: the new frontier of cancer genomics and therapeutics
    Giovanni Tonon
    Dana Farber Cancer Institute, Harvard Medical School Mayer Building, 44 Binney Street, Boston, MA 02115, USA
    Future Oncol 4:569-77. 2008
    ..The first subset of genes is frequently mutated across samples and tumor types, and includes well-studied oncogenes and tumor suppressor genes, such as members of the RAS, AKT and TP53 families, whose direct targeting has so far ..
  81. ncbi Chromosomal localization of human cellular homologues of two viral oncogenes
    N Heisterkamp
    Nature 299:747-9. 1982
  82. ncbi Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB
    R Aasland
    Laboratory of Biotechnology, University of Bergen, Norway
    Br J Cancer 57:358-63. 1988
    The receptor-type oncogenes c-erbB2/neu and c-erbB have been found amplified and/or overexpressed in a number of tumours of epithelial origin. We have studied the expression of oncogenes in biopsies from human thyroid tumours...
  83. ncbi Dissecting the genetic alterations involved in lung carcinogenesis
    Montserrat Sanchez-Cespedes
    Molecular Pathology Program, Spanish National Cancer Center, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Lung Cancer 40:111-21. 2003
    ..The present review describes the catalog of known genetic alterations and the recent advances in global expression profiles in lung tumors and briefly discusses their use in clinical management...
  84. ncbi Combinatorial patterns of somatic gene mutations in cancer
    Chen Hsiang Yeang
    Simons Center for Systems Biology, Institute for Advanced Study, Princeton, New Jersey 08540, USA
    FASEB J 22:2605-22. 2008
    ..The frequently mutated genes are well-known oncogenes and tumor suppressors that are involved in generic processes of cell-cycle control, signal transduction, and ..
  85. ncbi DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers
    W W Lockwood
    Department of Cancer Genetics, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Oncogene 27:4615-24. 2008
    ..Many recurrently amplified oncogenes were previously known to be activated only by disease-specific translocations...
  86. ncbi A systems biology approach for the study of cumulative oncogenes with applications to the MAPK signal transduction pathway
    Dhruv K Pant
    Drexel University, 3141 Chestnut St, Philadelphia, PA, 19104 United States
    Biophys Chem 119:49-60. 2006
    ..A second order sensitivity analysis scheme is additionally used to determine the effect of correlations among mutations at different sites in the pathways...
  87. ncbi miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells
    Shu Yang Xie
    Institute of Medical Molecular Genetics, Department of Biochemistry and Molecular Biology, Bin Zhou Medical University, Shandong 264003, PR China
    Oncol Rep 23:1693-700. 2010
    ..Our results showed that miR-16, miR-34a-c, miR-17-5p and miR-125 were up-regulated, and their associated oncogenes (BCL2, E2F1 and E2F3, respectively) were down-regulated after cisplatin treatment...
  88. ncbi Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes
    C Tran Quang
    Transcription Laboratory, Room 528, Imperial Cancer Research Fund Laboratories, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    EMBO J 19:4565-76. 2000
    ..These results implicate ROCK-mediated ezrin C-terminal phosphorylation in transformation by RhoGEFs...
  89. ncbi Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis
    P Laudanski
    Department of Perinatology, Medical University of Bialystok, ul Marii Sklodowskiej Curie 24a, Bialystok, Poland
    Hum Reprod 24:1880-90. 2009
    ..The aim of the study was to compare the expression level of mammalian target of rapamycin (mTOR) tumor suppressor and oncogene-related genes in the endometrium of women with and without endometriosis as well as in ovarian endometriosis...
  90. ncbi Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes
    E Hu
    Dana Farber Cancer Institute, Boston, MA 02115
    EMBO J 13:3094-103. 1994
    ..mRNA for the metalloproteases stromelysin (MMP-3) and type I collagenase (MMP-1), which are often induced by oncogenes and growth factors and have been implicated in tumor invasiveness, cannot be induced by epidermal growth factor ..
  91. ncbi ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer
    David P Turner
    Department of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
    Expert Rev Anticancer Ther 8:33-42. 2008
    ..Specific examples of altered ETS factor expression are highlighted, and therapeutic technologies that may be used to target ETS factors and their cofactors and downstream target genes in prostate cancer are discussed...
  92. ncbi "Hit-and-run" transformation by adenovirus oncogenes
    M Nevels
    , , D-93053 Regensburg, Germany
    J Virol 75:3089-94. 2001
    According to classical concepts of viral oncogenesis, the persistence of virus-specific oncogenes is required to maintain the transformed cellular phenotype...
  93. ncbi Role of STAT3 in in vitro transformation triggered by TRK oncogenes
    Claudia Miranda
    Operative Unit Molecular Mechanisms, Department of Experimental Oncology and Molecular Medicine, IRCCS Foundation, Istituto Nazionale dei Tumori, Milan, Italy
    PLoS ONE 5:e9446. 2010
    ..In this paper we have investigated STAT3 involvement in signalling induced by TRK oncogenes. We showed that TRK oncogenes trigger STAT3 phosphorylation both on Y705 and S727 residues and STAT3 ..
  94. ncbi E2F1 in gliomas: a paradigm of oncogene addiction
    Marta M Alonso
    Department of Neuro Oncology, Unit 1002, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Lett 263:157-63. 2008
    ..We also consider the clinical relevance of this by examining the role of E2F1 as a prognosis factor and as a target for the development of novel strategies...
  95. ncbi Modeling the dosage effect of oncogenes in leukemogenesis
    Ruibao Ren
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, MA 02454 9110, USA
    Curr Opin Hematol 11:25-34. 2004
    This review discusses the dosage effects of some oncogenes in leukemogenesis and compares various methods that model human hematologic malignancies in mice by introducing genetic lesions in a cell type-specific, time-controlled, and ..
  96. ncbi The RUNX genes: gain or loss of function in cancer
    Karen Blyth
    Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow Veterinary School, Glasgow, G61 1QH, UK
    Nat Rev Cancer 5:376-87. 2005
    ..their paradoxical effects in cancer, in which they can function either as tumour-suppressor genes or dominant oncogenes according to context...
  97. ncbi Slowing down the Ras lane: miRNAs as tumor suppressors?
    John P Morris
    UCSF Diabetes Center, Department of Microbiology and Immunology, University of California, San Francisco, CA 94122 0534, USA
    Sci STKE 2005:pe41. 2005
    ..This work raises several important questions: Can other miRNAs act as tumor suppressors or oncogenes? Is miRNA deregulation a critical aspect of tumor development and maintenance? A number of recent studies have ..
  98. ncbi The biology of cancer genetics
    Paula Trahan Rieger
    International Affairs, American Society of Clinical Oncology, Alexandria, VA 22306, USA
    Semin Oncol Nurs 20:145-54. 2004
    ..CONCLUSION: Several types of genetic damage occur in cancer cells: activation of protooncogenes into oncogenes that give cells an abnormal growth advantage; inactivation of tumor suppressor genes that would normally slow or ..
  99. ncbi Role of the nuclear matrix proteins in malignant transformation and cancer diagnosis
    Nikolajs Sjakste
    Faculty of Medicine of the University of Latvia, Riga LV1001, Latvia
    Exp Oncol 26:170-8. 2004
    ..II. Tumors with phenotypic quantitative or qualitative changes of the NMP spectrum...
  100. ncbi [Carcinogenesis of Barrett's esophagus]
    Takao Endo
    First Department of Internal Medicine, Sapporo Medical University
    Nippon Rinsho 63:1357-61. 2005
    ..The underlying disease mechanisms remain unclear, but tumor suppression genes (p53, p16, APC) and, oncogenes (K-ras, cyclin D1, c-erb-2) seem to cause the malignant transformation of Barrett's esophagus, and the genetic ..
  101. ncbi [Laser microdissection in the molecular oncology of prostate cancer]
    N Wernert
    Institut für Pathologie der Universität Bonn
    Urologe A 43:646-52. 2004
    ..A far reaching goal is the computer representation of multiple molecular components and their interactions, "E-cell in cyberspace", in which prognostic behaviour and therapeutic responsiveness can be approximately predicted...

Research Grants78

  1. Oncogene cooperation in glioma genesis
    WEI contact ZHANG; Fiscal Year: 2010
    Cancer development and progression involve activation of multiple oncogenes and inactivation of multiple tumor suppressor genes...
  2. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  3. GENETIC ANALYSIS OF POLARITY
    Ruth Steward; Fiscal Year: 2009
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  4. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
    Ruth Lupu; Fiscal Year: 2009
    ....
  5. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
    Ruth Lupu; Fiscal Year: 2007
    ....
  6. The Role of Cul4A in Genome Stability and Cancer Development
    Liang You; Fiscal Year: 2010
    ..This model may be used to study the role that Cul4A plays in mesothelioma carcinogenesis, and may also be potentially useful for further drug discovery, e.g., to screen for molecules that inhibiting Cul4A-mediated p21 degradation. ..
  7. MicroRNAs and chromosome 22q in the colon
    Anil Rustgi; Fiscal Year: 2009
    ..instability pathway, involving alterations in key tumor suppressor genes (APC and p53, but also SMAD4) and oncogenes (especially Ras, but also EGFR, c-myc, B-Raf) and their downstream effectors...
  8. S6 PHOSPHORYLATION AND TYROSINE PROTEIN KINASES
    JAMES MALLER; Fiscal Year: 1993
    The protein products of a number of retroviral oncogenes and growth factor receptors are protein tyrosine kinases...
  9. MicroRNAs and chromosome 22q in the colon
    Anil Rustgi; Fiscal Year: 2009
    ..instability pathway, involving alterations in key tumor suppressor genes (APC and p53, but also SMAD4) and oncogenes (especially Ras, but also EGFR, c-myc, B-Raf) and their downstream effectors...
  10. MicroRNAs and chromosome 22q in the colon
    Anil K Rustgi; Fiscal Year: 2010
    ..instability pathway, involving alterations in key tumor suppressor genes (APC and p53, but also SMAD4) and oncogenes (especially Ras, but also EGFR, c-myc, B-Raf) and their downstream effectors...
  11. STRUCTURE AND FUNCTION OF C-ABL PROTO-ONCOGENE
    Jean Wang; Fiscal Year: 1992
    ..c-abl proteins contain a tyrosine kinase domain which is essential to the transforming function of c-abl derived oncogenes. The ubiquitous expression of the c-abl gene suggests that it may serve a function common to all cells...
  12. Novel prostate cancer oncogenes identified by transposon mutagenesis
    Paul C Marker; Fiscal Year: 2010
    We have conducted a two-species pilot screen to discover new oncogenes and tumor suppressor genes that can drive prostate cancer initiation and/or progression in mice and humans...
  13. Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences
    Carol Lim; Fiscal Year: 2009
    ..Our long-term, ultimate goal is to use localization controllable versions of Bcr-Abl (as gene therapy) for treatment of CML. ..
  14. Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences
    Carol S Lim; Fiscal Year: 2010
    ..Our long-term, ultimate goal is to use localization controllable versions of Bcr-Abl (as gene therapy) for treatment of CML. ..
  15. MOLECULAR MECHANISMS IN METASTASIS
    Ruth Muschel; Fiscal Year: 1993
    ..The tumors formed by each combination of oncogenes also grow at equivalent rates although those formed by H-ras plus ElA appear to be encapsulated...
  16. THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENES
    Christopher Benz; Fiscal Year: 2002
    ....